HLS Therapeutics Inc.
HLS.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -12.43M | -14.12M | -15.04M | -17.99M | -19.66M |
| Total Depreciation and Amortization | 21.82M | 21.79M | 21.79M | 22.16M | 22.72M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.01M | 3.67M | 2.88M | 3.81M | 3.80M |
| Change in Net Operating Assets | 4.73M | 2.49M | 3.23M | 2.79M | 1.14M |
| Cash from Operations | 17.13M | 13.83M | 12.85M | 10.77M | 8.00M |
| Capital Expenditure | -205.00K | -185.00K | -121.00K | -34.00K | -15.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 0.00 | -1.50M | -1.50M | -1.50M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.50M | -1.22M | -1.00M | 13.25M | 13.25M |
| Cash from Investing | -1.70M | -1.40M | -2.62M | 11.72M | 11.74M |
| Total Debt Issued | 57.24M | 57.24M | -- | -- | -- |
| Total Debt Repaid | -75.61M | -73.07M | -29.49M | -22.46M | -21.57M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -1.80M | -1.79M | -1.01M | -493.00K | -600.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.39M | -1.22M | 0.00 | -658.00K | -1.19M |
| Cash from Financing | -21.56M | -18.84M | -30.49M | -23.61M | -23.36M |
| Foreign Exchange rate Adjustments | 396.00K | -348.00K | -100.00K | -584.00K | -870.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.73M | -6.76M | -20.36M | -1.71M | -4.50M |